Locoregional therapies for hepatocellular carcinoma : The current status and future perspectives
© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology..
Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
United European gastroenterology journal - 12(2024), 2 vom: 15. März, Seite 226-239 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jian-Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ueg2.12554 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368625079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368625079 | ||
| 003 | DE-627 | ||
| 005 | 20240409232450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ueg2.12554 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM368625079 | ||
| 035 | |a (NLM)38372444 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jian-Jian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Locoregional therapies for hepatocellular carcinoma |b The current status and future perspectives |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. | ||
| 520 | |a Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a combined modality therapy | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a locoregional therapy | |
| 650 | 4 | |a molecular targeted therapy | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Jin, Zhi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Bin-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Wenzhe |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Biao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yu-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Gao-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Hai-Dong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t United European gastroenterology journal |d 2013 |g 12(2024), 2 vom: 15. März, Seite 226-239 |w (DE-627)NLM237284804 |x 2050-6414 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:226-239 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ueg2.12554 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 2 |b 15 |c 03 |h 226-239 | ||